ArticleCancer medicine2023

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study.

Tianyue Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.